Poster: Epigenetic Target BRD3 – Fragment-based Hit Discovery

Sygnature Discovery has successfully created a unique fragment library, characterized by its high level of novelty and extensive coverage of chemical diversity. This proprietary library comprises more than 900 compounds, a significant portion of which are not commercially accessible. The library’s design was guided by the ‘rule of 3’ and focused on achieving a broad range of structural diversity.

To showcase the potential of this fragment-based drug discovery approach, Sygnature Discovery conducted a screening experiment using the library. The target selected for this study is the epigenetic protein Bromodomain-containing protein 3 (BRD3 or RING3L), an area of drug discovery with limited existing literature. The screening aimed to demonstrate the effectiveness of the library in identifying promising fragments for further drug development.

Download Poster

Poster download form with organisation field
Invalid email address provided.
Please only use your business email address.